Gujarat has started developing a region-specific antivenom based on venom from snakes native to the state. Scientists seek geographically representative products because venom composition varies across regions. India has long used one polyvalent antivenom. The first batch from this effort is expected within a year.
Gujarat recently transferred freeze-dried venom from four key venomous snakes to a licensed producer. This step follows increased research into regional venom differences. Experts note that venom makeup can change across the same species range, requiring tailored formulations and broader venom collection.
Current Indian antivenoms target the Indian cobra, common krait, Russell’s viper and saw-scaled viper. Venom is gathered from healthy snakes, processed and injected in measured amounts into horses. Antibodies are later extracted from the animals’ blood for human treatment. Most venom has come from one main supplier in Chengalpattu for decades.
Researchers question the uniform approach because venom contains varied proteins and enzymes shaped by local prey, habitat and genetics. Studies since 2007 have shown clear regional differences in cobra and other snake venoms. One analysis found that antibodies against eastern cobra venom worked best on eastern samples. A 2019 study reported weak performance of commercial antivenoms against several neglected species in lab tests.
Existing antivenoms have still saved many lives and remain standard care. Lab variations do not prove current products fail. Treatment success also depends on venom quantity, arrival time at facilities and supportive care. A recent policy review stresses that better antivenoms and stronger local health systems are both essential.
Region-specific antivenoms use venom from snakes in one area so the resulting antibodies match local toxin profiles more closely. Gujarat’s project follows this model.
